Gibson Dunn Advises Royalty Pharma on Acquisition of Royalty Interest in Amgen’s Imdelltra
Firm News | August 26, 2025
Gibson Dunn is representing Royalty Pharma plc in its acquisition of a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for up to $950 million.
Royalty Pharma will pay $885 million upfront, and BeOne retains the option to sell an additional portion of its royalty to Royalty Pharma for up to $65 million within the next 12 months, in exchange for an approximately 7% royalty on worldwide net sales of Imdelltra.
Our corporate team includes partners Karen Spindler, Ryan Murr, and associate Ayushi Sutaria.